BioCryst Pharmaceuticals
BCRX
$4.16
Share price
0.00%
Change (1 day)
-45.34%
Change (1 year)
Categories
BioCryst Pharmaceuticals (BCRX) - Cash on Hand
Cash on Hand as of December 2023 : $0.38 B
According to BioCryst Pharmaceuticals
's latest financial reports the company has $0.38 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
BioCryst Pharmaceuticals - Cash on Hand chart (from 2001 to 2023)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $0.38 B | -8.32% |
| 2022-12-31 | $0.42 B | -16.41% |
| 2021-12-31 | $0.50 B | 68.99% |
| 2020-12-31 | $0.30 B | 120.49% |
| 2019-12-31 | $0.13 B | 30.4% |
| 2018-12-31 | $0.10 B | -8.68% |
| 2017-12-31 | $0.11 B | 109.33% |
| 2016-12-31 | $54.65 M | 5.99% |
| 2015-12-31 | $51.56 M | -29.14% |
| 2014-12-31 | $72.77 M | 91.23% |
| 2013-12-31 | $38.05 M | 6.9% |
| 2012-12-31 | $35.59 M | -14.67% |
| 2011-12-31 | $41.71 M | -22.67% |
| 2010-12-31 | $53.94 M | -21.78% |
| 2009-12-31 | $68.96 M | 12.08% |
| 2008-12-31 | $61.52 M | 21.36% |
| 2007-12-31 | $50.69 M | 35.35% |
| 2006-12-31 | $37.45 M | -25.47% |
| 2005-12-31 | $50.26 M | 116.89% |
| 2004-12-31 | $23.17 M | 15.7% |
| 2003-12-31 | $20.02 M | -18.08% |
| 2002-12-31 | $24.44 M | -23.57% |
| 2001-12-31 | $31.98 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 Gilead Sciences GILD | $7.26 B | 1,767.41% | 🇺🇸 USA |
 GlaxoSmithKline GSK | $6.35 B | 1,533.68% | 🇬🇧 UK |
 Sarepta Therapeutics
SRPT | $1.67 B | 330.93% | 🇺🇸 USA |
 Repligen
RGEN | $0.75 B | 93.15% | 🇺🇸 USA |
 Novavax NVAX | $0.56 B | 46.15% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | $0.42 B | 8.90% | 🇺🇸 USA |
 NanoViricides NNVC | $5.24 M | -98.65% | 🇺🇸 USA |
 Cel-Sci
CVM | $3.24 M | -99.17% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | $0.11 B | -71.28% | 🇺🇸 USA |